亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Efficacy, safety, and optimal intervention of belimumab for proliferative lupus nephritis patients in real-world settings: LOOPS registry

医学 狼疮性肾炎 贝里穆马布 内科学 干预(咨询) 重症监护医学 免疫学 疾病 B细胞激活因子 抗体 B细胞 精神科
作者
H. Sakai,Yusuke Miyazaki,Shingo Nakayamada,Satoshi Kubo,Kentaro Hanami,Shunsuke Fukuyo,Ayako Yamaguchi,Ippei Miyagawa,M Ueno,Hiroaki Tanaka,Yasuyuki Todoroki,Naoaki Ohkubo,Masashi Funada,Satsuki Matsunaga,Yoshiya Tanaka
出处
期刊:Rheumatology [Oxford University Press]
标识
DOI:10.1093/rheumatology/keae495
摘要

Abstract Objectives This study investigated the efficacy, safety and predictive factors of belimumab (BEL) in induction therapy for patients with proliferative lupus nephritis (LN) in real-world settings. Methods Patients with biopsy-proven ISN/RPS class III or IV LN, with or without coexisting class V LN, who underwent standard of care (SoC), glucocorticoid (GC) and either mycophenolate mofetil or cyclophosphamide treatments were included. Participants were treated with SoC (SoC group, n = 32) or BEL and SoC (BEL+SoC group, n = 30). The primary end point was complete renal response (CRR) at 52 weeks. Results Baseline patient characteristics were not significantly different between the two groups. The 52-week retention rate of BEL was 90.0%. The BEL+SoC group showed significantly higher CRR and primary efficacy renal response achievement at 52 weeks and significantly lower GC dosage, adverse events and Systemic Lupus International Collaborating Clinics damage index scores. Multivariate analysis of CRR achievement at 52 weeks revealed that the lack of estimated glomerular filtration rate (eGFR) improvement at 4 weeks was associated with CRR failure in the SoC group. A shorter duration (cut-off of 42 days) between the start of induction therapy and addition of BEL was also related to the CRR in the BEL+SoC group. Conclusion BEL, in addition to SoC, controls disease activity, reduces GC use and suppresses organ damage in case of proliferative LN. Earlier BEL induction within 6 weeks may help achieve CRR in treatment-resistant cases without eGFR improvement at 4 weeks after induction therapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
ZaZa完成签到,获得积分10
2秒前
wyuanhu完成签到,获得积分10
7秒前
小芭乐完成签到 ,获得积分10
7秒前
奋斗的舒芙蕾完成签到,获得积分10
12秒前
16秒前
开心的瘦子完成签到,获得积分20
22秒前
JOSIELO完成签到 ,获得积分10
22秒前
23秒前
27秒前
程小柒完成签到 ,获得积分10
32秒前
34秒前
40秒前
Ghiocel完成签到,获得积分10
51秒前
57秒前
佟语雪完成签到,获得积分10
57秒前
轻松的惜芹应助喂喂采纳,获得10
1分钟前
淳于如雪发布了新的文献求助10
1分钟前
LLL完成签到 ,获得积分10
1分钟前
yar应助淳于如雪采纳,获得10
1分钟前
Koking关注了科研通微信公众号
1分钟前
1分钟前
淳于如雪完成签到,获得积分20
1分钟前
lv发布了新的文献求助10
1分钟前
我是老大应助吴嘉俊采纳,获得10
1分钟前
1分钟前
在水一方应助阿九采纳,获得10
1分钟前
1分钟前
ZT完成签到,获得积分10
1分钟前
搜集达人应助zhouleiwang采纳,获得10
1分钟前
吴嘉俊发布了新的文献求助10
1分钟前
仙人掌王朝完成签到,获得积分10
1分钟前
1分钟前
Hello应助zhouleiwang采纳,获得10
1分钟前
阿九完成签到,获得积分10
1分钟前
lllxxx完成签到 ,获得积分10
1分钟前
lv发布了新的文献求助10
1分钟前
冉亦完成签到,获得积分10
1分钟前
WGS完成签到,获得积分10
1分钟前
科研通AI2S应助科研通管家采纳,获得10
1分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990012
求助须知:如何正确求助?哪些是违规求助? 3532049
关于积分的说明 11256153
捐赠科研通 3270925
什么是DOI,文献DOI怎么找? 1805123
邀请新用户注册赠送积分活动 882270
科研通“疑难数据库(出版商)”最低求助积分说明 809216